Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System

BACKGROUND: Biosimilar products of rituximab came to market in 2017. French pharmacovigilance centers have highlighted an excess of case reports of severe hypersensitivity reactions related to their use compared with the originator product. OBJECTIVE: The aim of this study was to assess the real-wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Jourdain, Hugo, Hoisnard, Léa, Sbidian, Emilie, Zureik, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195743/
https://www.ncbi.nlm.nih.gov/pubmed/36877448
http://dx.doi.org/10.1007/s40259-023-00584-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195743/
https://www.ncbi.nlm.nih.gov/pubmed/36877448
http://dx.doi.org/10.1007/s40259-023-00584-8

Ejemplares similares